Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2019-09-26 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Half-year Report
Interim / Quarterly Report Classification · 1% confidence The document is titled 'HALF YEARLY REPORT FOR THE PERIOD ENDED 30 JUNE 2019' and contains comprehensive financial statements, including a consolidated statement of comprehensive income and a consolidated statement of changes in shareholders' equity. It provides detailed management commentary, operational highlights, and financial analysis for the interim period. It is not a mere announcement of a report, as it contains the full financial data and analysis required for an interim report. H1 2019
2019-09-26 English
Company Update
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and contains a date (24 September 2019) and company announcement regarding receiving an HMRC R&D Tax Credit (£0.423m). The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and explicit mention of RNS strongly indicate a general regulatory announcement that does not fit into more specific categories like 10-K, ER, or DIV. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short (4226 chars), but it is reporting a specific event (receipt of tax credit) rather than announcing the publication of a separate, larger report, making RNS more suitable than RPA.
2019-09-24 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document explicitly contains the header 'RNS Number : 8817L' and mentions 'RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' The content is a 'TR-1: Standard form for notification of major holdings,' which details changes in share ownership thresholds (from 5.29% to 2.36%). This type of regulatory disclosure regarding significant shareholdings is a specific type of filing. While it is a regulatory filing, the presence of 'RNS Number' and the nature of the announcement strongly suggest classification as a general Regulatory Filing (RNS) or potentially Major Shareholding Notification (MRQ). Since the document is a direct notification published via the RNS system, and MRQ is defined as 'Notification of changes in significant share ownership levels (crossing thresholds),' MRQ is the most precise fit for the content, even though it is distributed via RNS. However, given the explicit RNS branding and the structure being a standard regulatory form notification, RNS is also a strong candidate if MRQ is interpreted narrowly. Reviewing the definitions, MRQ specifically covers 'Major Shareholding Notification.' This document is exactly that. I will classify it as MRQ, as it is more specific than the general RNS fallback.
2019-09-10 English
VAL201 Update
Legal Proceedings Report Classification · 1% confidence The document begins with an 'RNS Number' and is dated, indicating it is a regulatory announcement from the London Stock Exchange's news service (RNS). The content is a press release titled 'VAL201 UPDATE' announcing clinical trial results and safety profiles for a therapeutic compound. It contains forward-looking statements and concludes with contact information typical of a public company announcement, explicitly stating, 'This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.' While it discusses clinical data, it is an announcement of findings, not a comprehensive Interim Report (IR) or Annual Report (10-K). Since it is a general regulatory announcement that doesn't fit the highly specific categories like DIV, DIRS, or ER, the most appropriate classification is the general regulatory filing category, RNS.
2019-09-10 English
Company Update & Change of Adviser
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated August 6, 2019. It contains several short updates regarding business discussions (joint venture status), expected receipt of a tax credit, and a change in the company's broker due to another firm entering Special Administration. The text explicitly states, 'This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.' The footer confirms the source: 'This information is provided by RNS, the news service of the London Stock Exchange.' Since this is a general, timely announcement of material, non-public information that doesn't fit the specific categories like ER, DIV, or DIRS, it falls under the general regulatory announcement category, RNS.
2019-08-06 English
New European patent allowance for VAL301
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated 01 August 2019. The content announces that the European Patent Office has issued a 'Patent Notice of Allowance' for a therapeutic compound (VAL301) and lists several patent grants/allowances across different jurisdictions. This is a specific corporate announcement regarding intellectual property and regulatory milestones, not a comprehensive financial report (like 10-K or IR) or a general earnings release (ER). Since it is a formal announcement distributed via RNS (London Stock Exchange's news service) that doesn't fit neatly into the other specific categories (like DIRS, DIV, MANG, etc.), the most appropriate classification is the general regulatory announcement category, RNS.
2019-08-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.